If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
the spin off....?
lol at £16 BN.
offers at a level they found acceptable were not forthcoming?.
That's how it looks to me.
£1 the next level..?
Thanks - I've requested LSE remove the post to avoid
any confusion - your reply is accurate.
which ..must end no last than 31 October 2022.
JDW are guiding for a FY pre tax loss and
Primark (ABF) appear 'unable ' to raise prices
to offset margin erosion.
This is getting serious.
He used to post on here a while back.
* there is
I would question that.
Why has Youngs' profitability returned to pre covid
levels approx, while FSTA appear to be under 50% of
their 2018 earnings.
Also their is family control of Fullers through ownership
of a different class of shares that are unlisted.
Anyone holding should understand the ownership/share
structure. The company sec may be able to help with this
if you want a detailed answer.
Mentioned this previously and it's beginning to look
more like we may be.
Load factor back to 96% and over 18 million passengers in one month,
fair does.
And how is that money repatriated form a Russian territory exactly?,
given the war. I thought there was a ban on money leaving Russia?.
about the future of the office ?.
Will offices largely become stranded assets?.
before the close
in that zone now at the close and I have started to add.
Possibly sub 60 pence a possibility, but if the latest acquisitions pay off
this arguably looks highly attractive - all IMV only as always.
Between 61-63.5 pence ? ..
I should stress the above is a guess Only.
I could not even guess at that.
There are potential litigation risks around medications,
GSK paid out $bn's in the US market on Advair -
but generated many more billions in pre tax profit
from Advair. From memory that was a
question of how the drug was marketed/sold -
rather than the compound itself.
Zantac was the medication that helped propel
GSK (Glaxo then) in to the big league.
It will not just be confined to the US market.
If this involves the prescription Zantac then we are looking
at the best selling drug globally by the late 1980's.
I was prescribed Zantac prior to the advent of proton pump inhibitors.
Like 99.99% of people I have little idea of how this ends.
an attempt at a subtle p1sstake?.
When you read posts such as..what is going on here..
Perhaps spend 60 seconds reading about last week's events.
To be fair that may leave you little the wiser
as possible litigation unknowns abound.
how do you even begin to quantify this.